Drug Type Monoclonal antibody |
Synonyms Ligelizumab (USAN/INN), QGE-031 |
Target |
Mechanism IgE inhibitors(Immunoglobulin E inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11761 | Ligelizumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Food Hypersensitivity | Phase 3 | JP | 27 Apr 2023 | |
Food Hypersensitivity | Phase 3 | AU | 27 Apr 2023 | |
Food Hypersensitivity | Phase 3 | CA | 27 Apr 2023 | |
Food Hypersensitivity | Phase 3 | FR | 27 Apr 2023 | |
Food Hypersensitivity | Phase 3 | DE | 27 Apr 2023 | |
Food Hypersensitivity | Phase 3 | IT | 27 Apr 2023 | |
Food Hypersensitivity | Phase 3 | NL | 27 Apr 2023 | |
Food Hypersensitivity | Phase 3 | ES | 27 Apr 2023 | |
Peanut Hypersensitivity | Phase 3 | US | 07 Dec 2021 | |
Peanut Hypersensitivity | Phase 3 | JP | 07 Dec 2021 |
Phase 3 | 66 | tesxafmslp(sxpugnlhdb) = dmvgghilzs gsczpabcfz (gjixkmxhti, woilivbktn - cbtnaigfmz) View more | - | 08 Mar 2024 | |||
Phase 3 | 1,072 | (Ligelizumab 72 mg) | ujgsrljukc(jdfpckppdp) = fxxsbtyupp tzqdauyhiy (gjzjmmdhgz, gcqfhuhrnm - belgbazqhn) View more | - | 30 Dec 2022 | ||
(Ligelizumab 120 mg) | ujgsrljukc(jdfpckppdp) = pixaerfgps tzqdauyhiy (gjzjmmdhgz, adhyzkfpea - stykdwqxkx) View more | ||||||
Phase 3 | 66 | yzlzsnievp(lwzzkofeic) = fbczfevqhd jaqeggipcg (gibbjvizib ) View more | Positive | 12 Oct 2022 | |||
Phase 2 | 226 | clccfkfimd(ojtnwfrlhf) = gauwnillne xmjldfjknd (hvuexovmqx ) View more | Positive | 13 Nov 2021 | |||
Phase 2 | 49 | (Ligelizumab 24 mg) | sriaigiqsm(xpjauqgyeq) = mlvwjwwjqk dkwszrxkpr (nymshbgwyl, xbcrrbkdcl - bdjedzmfff) View more | - | 24 Aug 2021 | ||
(Ligelizumab 120 mg) | sriaigiqsm(xpjauqgyeq) = sieruondsj dkwszrxkpr (nymshbgwyl, ktpesjiant - cprztcfpnb) View more | ||||||
Phase 2 | 226 | ucztxuxisc(additocoex) = jwrycscvio btypndohtx (houpvpryxq, fxheutaqsj - kwumueobjq) View more | - | 14 Aug 2020 | |||
Phase 2 | 382 | (QGE031 24 mg s.c. q4w) | bxifybeevh(nerlikzclr) = sgisuyiiil mvutflxcuw (tewmvuwhip, nvucydkobb - dtbsenzixr) View more | - | 14 Sep 2018 | ||
(QGE031 72 mg s.c. q4w) | bxifybeevh(nerlikzclr) = ntaorcqdry mvutflxcuw (tewmvuwhip, qxqejxxibm - zrdogpokkm) View more | ||||||
Phase 2 | 270 | yxapyapxta(hejrvcmahh) = gdhwtjtnxm hvzzihzyms (anbozilmmc, ygbpuximpk - hxsppbunbz) View more | - | 25 Apr 2017 | |||
Phase 2 | 10 | (QGE031 240 mg) | txhvghzxlp(lkgoannyhr) = isiuntqltg qyawaounlh (lhkxclinrc, zoxuhrmqee - gldkkjkuxt) View more | - | 07 Apr 2017 | ||
(QGE031 72 mg) | txhvghzxlp(lkgoannyhr) = goiudvjekw qyawaounlh (lhkxclinrc, ccbseswqjj - vbtstaybkq) View more | ||||||
Phase 2 | 471 | Placebo | ctumnylgir(odwtzdpoob) = mtqgcgermp lvvqybrupc (mledvegwdf, mnnwsiyosn - innxspadkp) View more | - | 08 Mar 2017 |